ArticleDiscover oncology2026
Meta learning optimized TabNet for small sample repeat prostate biopsy prediction.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeRepeat prostate biopsy prediction remains limited by small patient cohorts that constrain artificial intelligence application despite theoretical advantages in capturing complex clinical patterns. This study develops and validates a meta-learning optimized TabNet framework using readily available clinical parameters to overcome sample size constraints and enhance repeat biopsy (RB) prediction accuracy through knowledge transfer from larger initial biopsy (IB) cohorts, with particular applicability to resource-limited settings where mpMRI remains unavailable. Meta-learning enables rapid model adaptation by leveraging knowledge from related tasks with minimal training examples.
methodsThis retrospective study analyzed 2,087 initial prostate biopsies and 139 subsequent RBs without mpMRI data. A two-stage training paradigm implemented Model-Agnostic Meta-Learning for pre-training on IB data, followed by fine-tuning on the RB cohort. Performance evaluation included discrimination analysis, calibration assessment, and decision curve analysis compared to original TabNet and conventional machine learning approaches, with classification performance benchmarked against established clinical risk calculators.
resultsAmong 139 RB patients, cancer was detected in 40 cases (28.8%), including 31 clinically significant cancers (75.5%). On the independent testing set of 42 patients, meta-learning TabNet achieved superior discriminative performance (AUROC 0.872) compared to XGBoost (0.808), original TabNet (0.800), and conventional approaches. The model demonstrated optimal calibration (Brier score 0.068, ECE 0.100) and high specificity (90.0%) with only three false positives, substantially outperforming ERSPC and PCPT calculators.
conclusionMeta-learning optimization successfully addresses sample size limitations in repeat prostate biopsy prediction without requiring advanced imaging. This provides an evidence-based decision support tool enhancing diagnostic accuracy while minimizing unnecessary procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.